Claims
- 1. A method for treating a mammal suffering from a life threatening level of red blood cell hemoglobin (RBC Hb) as the result of blood loss comprising administering to the mammal a polymerized hemoglobin solution.
- 2. The method of claim 1 wherein the hemoglobin solution is an acellular solution comprising an essentially tetramer-free, cross-linked, polymerized hemoglobin solution which is substantially free of stroma and other contaminants.
- 3. The method of claim 1 wherein the blood loss is a massive blood loss.
- 4. The method of claim 1 wherein the hemoglobin solution is administered in an amount of at least 5 L.
- 5. The method of claim 1 wherein the hemoglobin solution is administered in an amount of at least one blood volume of the mammal.
- 6. The method of claim 1 wherein the administration of the hemoglobin solution maintains a mean circulating hemoglobin level greater than 5.0 g/dL.
- 7. The method of claim 1 wherein the administration of the hemoglobin solution maintains arterial pressure above 60 mmHg.
- 8. The method of claim 1 wherein the hemoglobin solution is administered at a rate of at least about 2 units per minute.
- 9. The method of claim 1 wherein the solution avoids the toxicities associated with vasoconstriction, and renal, pancreatic, gastrointestinal and cardiac dysfunction.
- 10. A method according to claim 1, wherein the polymerized hemoglobin has a molecular weight distribution of:
(a) from about 5-30% by weight of polymerized hemoglobin of polymer having a molecular weight of about 128 KDa; (b) from about 15-35% by weight of polymerized hemoglobin of polymer having a molecular weight of about 192 KDa; and (c) from about 35-75% by weight of polymerized hemoglobin of polymer having a molecular weight of about 256 KDa.
- 11. The method of claim 1 wherein the life threatening level of RBC Hb is less than 3.0 g/dL.
- 12. A method of preventing anemia, irreversible ischemia, or hypovolemic shock in a patient suffering from massive blood loss comprising administering to the patient a volume of a polymerized hemoglobin solution sufficient to maintain total Hb above 5.0 g/l and arterial pressure above 60 mmHg.
- 13. The method of claim 12 wherein hemoglobin solution is an acellular solution comprising an essentially tetramer-free, cross-linked, polymerized hemoglobin solution which is substantially free of stroma and other contaminants.
- 14. The method of claim 12 wherein prior to treatment the patient's level RBC Hb is less than 5.0 g/dL.
- 15. The method of claim 12 wherein prior to treatment the patient's level RBC Hb is less than 3.0 g/dL.
- 16. The method of claim 12 wherein the hemoglobin solution is administered in an amount of at least 5 L.
- 17. The method of claim 12 wherein the hemoglobin solution is administered in an amount of at least one blood volume of the mammal.
- 18. The method of claim 12 wherein the administration of the hemoglobin solution maintains arterial pressure above 60 mmHg.
- 19. The method of claim 12 wherein the hemoglobin solution is administered at a rate of at least about 2 units per minute.
- 20. The method of claim 12 wherein the solution avoids the toxicities associated with vasoconstriction, and renal, pancreatic, gastrointestinal and cardiac dysfunction.
- 21. A method according to claim 12, wherein the polymerized hemoglobin has a molecular weight distribution of:
(a) from about 5-30% by weight of polymerized hemoglobin of polymer having a molecular weight of about 128 KDa; (b) from about 15-35% by weight of polymerized hemoglobin of polymer having a molecular weight of about 192 KDa; and (c) from about 35-75% by weight of polymerized hemoglobin of polymer having a molecular weight of about 256 KDa.
- 22. A method of maintaining mean circulating Hb levels above 5.0 g/dL in a patient suffering from massive blood loss comprising administering to the patient a polymerized hemoglobin solution in an amount of at least one blood volume of the patient.
- 23. The method of claim 22 wherein hemoglobin solution is an acellular solution comprising an essentially tetramer-free, cross-linked, polymerized hemoglobin solution which is substantially free of stroma and other contaminants.
- 24. A method according to claim 23, wherein the polymerized hemoglobin has a molecular weight distribution of:
(a) from about 5-30% by weight of polymerized hemoglobin of polymer having a molecular weight of about 128 KDa; (b) from about 15-35% by weight of polymerized hemoglobin of polymer having a molecular weight of about 192 KDa; and (c) from about 35-75% by weight of polymerized hemoglobin of polymer having a molecular weight of about 256 KDa.
- 25. The method of claim 22 wherein the hemoglobin solution is administered in an amount of at least 5 L.
- 26. The method of claim 22 wherein the hemoglobin solution is administered in an amount of at least one blood volume of the mammal.
- 27. The method of claim 22 wherein the administration of the hemoglobin solution maintains arterial pressure above 60 mmHg.
- 28. The method of claim 22 wherein the hemoglobin solution is administered at a rate of at least about 2 units per minute.
- 29. The method of claim 23 wherein the solution avoids the toxicities associated with vasoconstriction, and renal, pancreatic, gastrointestinal and cardiac dysfunction.
- 30. A method for treating a human having a hemoglobin concentration below about 7 g/dL as the result of a massive blood loss and, comprising administering to the human a polymerized hemoglobin solution.
- 31. The method of claim 30 wherein hemoglobin solution is an acellular solution comprising an essentially tetramer-free, cross-linked, polymerized hemoglobin solution which is substantially free of stroma and other contaminants.
- 32. The method of claim 30 wherein the hemoglobin solution is administered in an amount of at least 5 L.
- 33. The method of claim 30 wherein the hemoglobin solution is administered in an amount of at least one blood volume of the mammal.
- 34. The method of claim 30 wherein the administration of the hemoglobin solution maintains a mean circulating hemoglobin level greater than 5.0 g/dL.
- 35. The method of claim 30 wherein the administration of the hemoglobin solution maintains arterial pressure above 60 mmHg.
- 36. The method of claim 30wherein the hemoglobin solution is administered at a rate of at least about 2 units per minute.
- 37. The method of claim 30 wherein the solution avoids the toxicities associated with vasoconstriction, and renal, pancreatic, gastrointestinal and cardiac dysfunction.
- 38. A method according to claim 30, wherein the polymerized hemoglobin has a molecular weight distribution of:
(a) from about 5-30% by weight of polymerized hemoglobin of polymer having a molecular weight of about 128 KDa; (b) from about 15-35% by weight of polymerized hemoglobin of polymer having a molecular weight of about 192 KDa; and (c) from about 35-75% by weight of polymerized hemoglobin of polymer having a molecular weight of about 256 KDa.
- 39. A method for sustaining life in a human suffering from massive blood loss comprising preventing hypovolemic shock and further decrease in blood pressure by administering to the human a polymerized hemoglobin solution.
- 40. A method according to claim 39, where and the human has a hemoglobin concentration below about 7 g/dL.
- 41. The method of claim 39 wherein hemoglobin solution is an acellular solution comprising an essentially tetramer-free, cross-linked, polymerized hemoglobin solution which is substantially free of stroma and other contaminants.
- 42. The method of claim 39 wherein the hemoglobin solution is administered in an amount of at least 5 L.
- 43. The method of claim 39 wherein the hemoglobin solution is administered in an amount of at least one blood volume of the mammal.
- 44. The method of claim 39 wherein the administration of the hemoglobin solution maintains arterial pressure above 60 mmHg.
- 45. The method of claim 39 wherein the hemoglobin solution is administered at a rate of at least about 2 units per minute.
- 46. The method of claim 39 wherein the solution avoids the toxicities associated with vasoconstriction, and renal, pancreatic, gastrointestinal and cardiac dysfunction.
- 47. A method according to claim 39, wherein the polymerized hemoglobin has a molecular weight distribution of:
(a) from about 5-30% by weight of polymerized hemoglobin of polymer having a molecular weight of about 128 KDa; (b) from about 15-35% by weight of polymerized hemoglobin of polymer having a molecular weight of about 192 KDa; and (c) from about 35-75% by weight of polymerized hemoglobin of polymer having a molecular weight of about 256 KDa.
RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/415,935, filed Oct. 3, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60415935 |
Oct 2002 |
US |